Related Experiment Video
Updated: Apr 14, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
Michael W Dunne1, Dan Sahm2, Sailaja Puttagunta3
1Durata Therapeutics, Inc., Branford, CT, Branford, CT, USA. mdunne@duratatx.com.
Background:
Dalbavancin is a lipoglycopepetide antibiotic with activity against gram positive pathogens recently approved for treatment of acute bacterial skin and skin structure infections. Pending the introduction of antimicrobial susceptibility tests, we examined the utility of vancomycin inhibitory concentrations to predict dalbavancin susceptibility in a panel of isolates obtained from phase 3 registration studies.
Findings:
99.6% of Staphylococcus aureus and 99.0% of beta-hemolytic streptococci which are susceptible to vancomycin will have an MIC at or below the US FDA susceptibility breakpoint for dalbavancin.
Conclusion:
Vancomycin should be considered as a surrogate for in vitro dalbavancin susceptibility testing.
Related Concept Videos
Automated Microbial Diagnostics
Estimation of k and VD of Aminoglycosides
In Vitro Drug Dissolution: Compendial Testing Models I
In Vitro Drug Dissolution: Compendial Testing Models II
Antimicrobial Effectiveness
In Vitro Drug Dissolution: Alternative Methods

